First-in-man clinical study of SCMod1 [Modi-1] for cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs SCMod1 (Primary)
- Indications Breast cancer; Endometrial cancer; Osteosarcoma; Ovarian cancer
- Focus Adverse reactions; First in man
- 13 Sep 2017 According to a Scancell media release, the company is aiming to file a Clinical Trial Application (CTA) in the UK for the planned Phase 1/2 clinical trial in breast cancer, ovarian cancer and sarcoma in 2018.
- 16 Sep 2016 According to Scancell media release, enrolment for triple negative breast cancer, ovarian cancer and osteosarcoma expected to commence in early 2018.
- 27 Jan 2016 According to a Scancell media release, clinical studies are scheduled to start in 2017.